Clinical Trials · NCT00283803
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- University of Washington
- Enrollment
- 32
- Start date
- Mar 2002
- Locations
- 1 site, United States
- Primary endpoint
- Duration of the First "Off-treatment" Cycle in Patients Who Have Completed One Cycle of Intermittent Androgen Suppression With the Addition of Exisulind.